RET and non-small cell lung carcinoma: In papillary thyroid carcinoma (PTC) and non-small cell lung cancer (NSCLC), RET fusion proteins that are constitutively active and promote tumor growth have been identified in 13-43% and 2% of patients, respectively (27–29).